Changyao Group(SZ:300391) Zheng Quan Zhi Xing·2025-08-25 17:05Core Viewpoint - The company has corrected accounting errors in its Q1 2025 financial report, specifically affecting revenue and cost figures, but these corrections do not impact overall profit or the balance sheet [1][2][4]. Accounting Error Correction - The company held a board meeting on August 22, 2025, to approve the correction of accounting errors in the Q1 2025 financial report, following relevant accounting standards and disclosure rules [1][4]. - The correction involved changing the recognition of certain trade transactions from "gross method" to "net method" based on the principle of prudence [1][2]. Financial Impact - The correction affects the following financial metrics for Q1 2025: - Total operating revenue was adjusted from 103,683,885.34 CNY to 45,795,675.76 CNY, a decrease of 57,888,209.58 CNY [2][3]. - Total operating costs were adjusted from 164,016,116.81 CNY to reflect the same decrease in revenue [2][3]. - The adjusted operating revenue shows a year-on-year decrease of 22.50%, attributed to a decline in the pharmaceutical segment's income [3]. Independent and Audit Committee Opinions - The independent directors and audit committee have reviewed the corrections and agree that they comply with relevant regulations, enhancing the accuracy and quality of the financial information [4][5]. Future Measures - The company emphasizes its commitment to improving the quality of information disclosure and plans to enhance training for financial personnel to prevent similar issues in the future [4].